A citation-based method for searching scientific literature

Jacob J Adashek, Vivek Subbiah, Razelle Kurzrock. Trends Cancer 2021
Times Cited: 23







List of co-cited articles
100 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy.
Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Amelie Boichard, Mina Nikanjam, Elizabeth Weihe, Dennis J Kuo, Ramez N Eskander, Aaron Goodman, Natalie Galanina,[...]. Nat Commun 2020
54
26

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
21

Transcriptomic silencing as a potential mechanism of treatment resistance.
Jacob J Adashek, Shumei Kato, Rahul Parulkar, Christopher W Szeto, J Zachary Sanborn, Charles J Vaske, Stephen C Benz, Sandeep K Reddy, Razelle Kurzrock. JCI Insight 2020
13
30

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller,[...]. Lancet Oncol 2020
428
17

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
385
17

NTRK fusion-positive cancers and TRK inhibitor therapy.
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon. Nat Rev Clin Oncol 2018
494
17

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Maria Schwaederle, Michael E Hahn, Casey B Williams, Pradip De, Amy Krie, David E Piccioni, Vincent A Miller,[...]. Nat Med 2019
218
17


Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
13

Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy.
Aaron M Goodman, Ethan S Sokol, Garrett M Frampton, Scott M Lippman, Razelle Kurzrock. Cancer Immunol Res 2019
78
13

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Mariangela Russo, Sandra Misale, Ge Wei, Giulia Siravegna, Giovanni Crisafulli, Luca Lazzari, Giorgio Corti, Giuseppe Rospo, Luca Novara, Benedetta Mussolin,[...]. Cancer Discov 2016
187
13

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
David S Hong, Steven G DuBois, Shivaani Kummar, Anna F Farago, Catherine M Albert, Kristoffer S Rohrberg, Cornelis M van Tilburg, Ramamoorthy Nagasubramanian, Jordan D Berlin, Noah Federman,[...]. Lancet Oncol 2020
240
13

Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology.
Denis Horgan, Gennaro Ciliberto, Pierfranco Conte, David Baldwin, Luis Seijo, Luis M Montuenga, Luis Paz-Ares, Marina Garassino, Frederique Penault-Llorca, Fabrizia Galli,[...]. Biomed Hub 2020
5
60

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
132
13

Pan-cancer whole-genome analyses of metastatic solid tumours.
Peter Priestley, Jonathan Baber, Martijn P Lolkema, Neeltje Steeghs, Ewart de Bruijn, Charles Shale, Korneel Duyvesteyn, Susan Haidari, Arne van Hoeck, Wendy Onstenk,[...]. Nature 2019
271
13

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, Herbert H F Loong, Melissa Johnson, Justin Gainor, Caroline E McCoach, Oliver Gautschi, Benjamin Besse, Byoung C Cho,[...]. N Engl J Med 2020
170
13

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
Jacob J Adashek, Ishwaria M Subbiah, Ignacio Matos, Elena Garralda, Arjun K Menta, Dhakshina Moorthy Ganeshan, Vivek Subbiah. Trends Cancer 2020
41
13

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
Jacob J Adashek, Shumei Kato, Roberto Ferrara, Giuseppe Lo Russo, Razelle Kurzrock. Oncologist 2019
22
13

Molecular profiling for precision cancer therapies.
Eoghan R Malone, Marc Oliva, Peter J B Sabatini, Tracy L Stockley, Lillian L Siu. Genome Med 2020
145
13

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F Mosele, J Remon, J Mateo, C B Westphalen, F Barlesi, M P Lolkema, N Normanno, A Scarpa, M Robson, F Meric-Bernstam,[...]. Ann Oncol 2020
180
13

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Brian I Rini, Elizabeth R Plimack, Viktor Stus, Rustem Gafanov, Robert Hawkins, Dmitry Nosov, Frédéric Pouliot, Boris Alekseev, Denis Soulières, Bohuslav Melichar,[...]. N Engl J Med 2019
8

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Robert J Motzer, Brian I Rini, David F McDermott, Osvaldo Arén Frontera, Hans J Hammers, Michael A Carducci, Pamela Salman, Bernard Escudier, Benoit Beuselinck, Asim Amin,[...]. Lancet Oncol 2019
332
8

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Robert J Motzer, Konstantin Penkov, John Haanen, Brian Rini, Laurence Albiges, Matthew T Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Negrier, Motohide Uemura,[...]. N Engl J Med 2019
8

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
D J McGrail, P G Pilié, N U Rashid, L Voorwerk, M Slagter, M Kok, E Jonasch, M Khasraw, A B Heimberger, B Lim,[...]. Ann Oncol 2021
132
8

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Filipe Martins, Latifyan Sofiya, Gerasimos P Sykiotis, Faiza Lamine, Michel Maillard, Montserrat Fraga, Keyvan Shabafrouz, Camillo Ribi, Anne Cairoli, Yan Guex-Crosier,[...]. Nat Rev Clin Oncol 2019
504
8

The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors.
Benoit Rousseau, Michael B Foote, Steven B Maron, Bill H Diplas, Steve Lu, Guillem Argilés, Andrea Cercek, Luis A Diaz. N Engl J Med 2021
39
8


Neoadjuvant checkpoint blockade for cancer immunotherapy.
Suzanne L Topalian, Janis M Taube, Drew M Pardoll. Science 2020
205
8


Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.
Antonia R Sepulveda, Stanley R Hamilton, Carmen J Allegra, Wayne Grody, Allison M Cushman-Vokoun, William K Funkhouser, Scott E Kopetz, Christopher Lieu, Noralane M Lindor, Bruce D Minsky,[...]. J Clin Oncol 2017
176
8

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Jean-Yves Douillard, Kelly S Oliner, Salvatore Siena, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, Gyorgy Bodoky, David Cunningham, Jacek Jassem,[...]. N Engl J Med 2013
8

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip P Patel, Garrett M Frampton, Vincent Miller, Philip J Stephens, Gregory A Daniels, Razelle Kurzrock. Mol Cancer Ther 2017
8

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
David S Hong, Marwan G Fakih, John H Strickler, Jayesh Desai, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Timothy J Price, Adrian Sacher, Crystal S Denlinger,[...]. N Engl J Med 2020
406
8

Hereditary colorectal cancer.
Henry T Lynch, Albert de la Chapelle. N Engl J Med 2003
8

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Leigh Marcus, Steven J Lemery, Patricia Keegan, Richard Pazdur. Clin Cancer Res 2019
387
8

Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Cinta Hierro, Ignacio Matos, Juan Martin-Liberal, Maria Ochoa de Olza, Elena Garralda. Clin Cancer Res 2019
18
11

Testing algorithm for identification of patients with TRK fusion cancer.
Frédérique Penault-Llorca, Erin R Rudzinski, Antonia R Sepulveda. J Clin Pathol 2019
79
8

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
179
8

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors.
Kyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, Ryohei Katayama, Yuki Shimizu, Viola W Zhu, Thomas Yang Sun, Heather A Wakelee, Russell Madison, Alexa B Schrock,[...]. Clin Cancer Res 2020
27
8

First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
Steven Lemery, Patricia Keegan, Richard Pazdur. N Engl J Med 2017
310
8

Larotrectinib: First Global Approval.
Lesley J Scott. Drugs 2019
78
8

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Robert C Doebele, Lara E Davis, Aria Vaishnavi, Anh T Le, Adriana Estrada-Bernal, Stephen Keysar, Antonio Jimeno, Marileila Varella-Garcia, Dara L Aisner, Yali Li,[...]. Cancer Discov 2015
238
8

Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics.
Ryosuke Okamura, Amélie Boichard, Shumei Kato, Jason K Sicklick, Lyudmila Bazhenova, Razelle Kurzrock. JCO Precis Oncol 2018
148
8

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Theodore W Laetsch, Steven G DuBois, Leo Mascarenhas, Brian Turpin, Noah Federman, Catherine M Albert, Ramamoorthy Nagasubramanian, Jessica L Davis, Erin Rudzinski, Angela M Feraco,[...]. Lancet Oncol 2018
259
8

TRKing down an old oncogene in a new era of targeted therapy.
Aria Vaishnavi, Anh T Le, Robert C Doebele. Cancer Discov 2015
324
8

Entrectinib: First Global Approval.
Zaina T Al-Salama, Susan J Keam. Drugs 2019
46
8

Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Jaclyn F Hechtman, Ryma Benayed, David M Hyman, Alexander Drilon, Ahmet Zehir, Denise Frosina, Maria E Arcila, Snjezana Dogan, David S Klimstra, Marc Ladanyi,[...]. Am J Surg Pathol 2017
219
8

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh,[...]. N Engl J Med 2019
756
8


Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.